Purpose: To compare a Baerveldt implant and trabeculectomy with respect to intraocular pressure (IOP) and failure rate at 1 year of follow-up. Secondary outcomes are pharmacological therapy and complications at 1 year of follow-up. Methods: This was a randomized, comparative study. A total of 119 glaucoma patients without previous ocular surgery were included at the Rotterdam Eye Hospital, the Netherlands. One eye of each subject was randomized to either a Baerveldt glaucoma drainage device (BGI) or trabeculectomy (TE). Follow-up visits were conducted at 1 day, 2 weeks, 6 weeks, 3 months, 6 months and 1 year after surgery. Results: After one year, the final IOP was equivalent for both treatment groups: 14 AE 4 mmHg (mean AE SD) for the Baerveldt group versus 13 AE 4 mmHg for the trabeculectomy group. Statistically, we found no significant difference in failure rate between the two groups. However, the Baerveldt group needed significantly more medication to decrease IOP. Overall, self-limiting complication rate was similar in both groups. Diplopia, a serious complication, was significantly more present in the BGI group. Conclusion: One year after surgery, TE shows better results than the BGI. The final IOP, IOP reduction and failure rate are similar, but the need for additional IOP lowering medication in the BGI group is higher as well as the complication rate. The increased risk of developing diplopia after placement of a BGI must be taken into consideration.
Introduction
As yet, the only evidence-based treatment for glaucoma is to reduce the intraocular pressure (IOP) (Giangioacomo & Coleman 2009 ). Interventions to control IOP and minimize the damage in glaucomatous eyes include pharmacological therapy, laser treatment and surgical intervention. As IOP levels can be very well controlled by surgery, which is less dependent on compliance to medication, ophthalmologists are increasingly inclined to perform surgery at an earlier stage (Ngoei 2011) . Trabeculectomy (TE) remains the standard surgical procedure, followed by glaucoma drainage devices (GDD) when TE fails to control IOP (Patel & Pasquale 2010) . Nevertheless, a shift has occurred towards GDD as the primary choice, instead of TE (Ramulu et al. 2007; Desai et al. 2011) .
Among GDD, the Ahmed and Baerveldt glaucoma implants (BGI) are the most often used. As a choice after TE, both have been prospectively compared to TE (Wilson et al. 2003; Minckler et al. 2008; Gedde et al. 2012) . When considering BGI as primary choice, the only comparison to TE was a retrospective study by Panarelli and co-authors, up to this date (Panarelli et al. 2016) .
The aim of this study was to compare the outcomes of TE and BGI in glaucomatous patients without previous ocular surgery. To our knowledge, such comparison has not yet been conducted in this population with this type of implant. Below, we hope to provide information that will help the surgeon to choose the best surgical procedure for such patients.
Materials and Methods
We performed a prospective, randomized, controlled clinical trial of two surgical interventions. The study was approved by the medical ethical committee of the Erasmus Medical Center (Rotterdam) and was registered at www.trialregister. nl (identifier NTR1142). The study protocol adhered to the tenets of the Declaration of Helsinki. Patients were selected at the outpatient department of glaucoma of the Rotterdam Eye Hospital and eligibility was independently confirmed by our research team.
Inclusion criteria were age (18-75 years) , primary open-angle glaucoma, normal tension glaucoma (NTG), pseudo exfoliative glaucoma or pigmentary glaucoma, the need for IOP lowering surgery, and Caucasian. The latter has been added to the inclusion criteria as previous studies showed that there is a difference in TE success rate between different races (Broadway et al. 1994 ) (Ederer et al. 2004) . By including only Caucasian patients, a homogeneous group is guaranteed.
Exclusion criteria consisted of history of any ocular surgery, such as TE or cataract extraction. As studies concluded that previous surgeries may influence the IOP control, we decided to exclude all forms of ocular surgeries (de Vries et al., 2016) . Other exclusion criteria are history of active uveitis or diabetic retinopathy, pregnancy or lactation, anticipated glaucoma surgery combined with other ocular procedures (i.e. cataract surgery), narrow anterior chamber angle interfering with tube implantation (i.e. 180°/270°of iridotrabecular contact), best-corrected visual acuity less than 0.1 in the study eye or fellow eye and history of ocular motility disturbances.
Only one eye per patient was included. All patients received full explanation of the study and written informed consent was obtained. We assigned patients randomly to either trabeculectomy with mitomycin-C (MMC) or implantation of a 350 mm 2 Baerveldt glaucoma device.
Surgical procedures
All patients were operated by the same surgeon (PdW) Trabeculectomy with Mitomycin-C (MMC): the surgeon made a limbusbased conjunctival/Tenon's flap, and after dissection, applied two sponges (Willow sponÒ) with 0.2 mg/ml MMC to the sclera and conjunctival/tenon for one minute. A scleral flap was dissected (6 9 4 mm) and two interrupted nylon 10-0 sutures were preplaced. The surgeon removed a block of limbus (1.5 mm in diameter) from underneath the scleral flap with a Crozafon-De Laage punch (MoriaÒ) and performed a peripheral iridectomy. After tying nylon 10-0 sutures, the anterior chamber was reconstructed and additional interrupted nylon 10-0 sutures were placed until the chamber was stable. The conjunctiva and Tenon's capsule were closed with a running suture (nylon 10-0). Postoperative laser suture lysis was performed at the surgeon's discretion in case of inadequate filtration.
Baerveldt glaucoma implants (BGI): A limbus-based conjunctival/Tenon's flap was used to place the BGI (BG-101-350, Advanced Medical Optics Inc. Santa Ana, CA, USA) in the superotemporal quadrant underneath the lateral and superior rectus muscles. The plate was sutured to the sclera and the surgeon occluded the tube with a single vicryl 7-0 suture. Then, the tube was sized to AE2 mm anterior to the limbus. Through an entry to the anterior chamber behind the limbus, the tip of the tube was positioned with the bevel up at a maximal distance of the corneal endothelium and anterior to the iris. Afterwards, the tube was covered with a graft of donor sclera. One fenestration was made by applying 1 nylon 9.0 suture through the tube. This procedure was standard among all patients with a BGI. The conjunctiva and Tenon's capsule were closed with a running suture (vicryl 7-0) .
At the end of both surgical procedures, a CelestoneÒ Chronodose (betamethasone phosphate/betamethasone acetate) injection was administered in the inferior subconjunctival space and DexamytrexÒ (Dexamethasone/gentamycin) eye ointment was inserted into the eye before closing with an eye bandage. From the first day after surgery, the patients used PredforteÒ drops (prednisolone acetate 10 mg/ml) 6 times daily during one month, after which the drops were tapered with one drop on a weekly base (9 to 10 weeks in total). UltracortenolÒ (prednisolone pivalate) was used at night time for the full period. Intraocular pressure (IOP) lowering medication was prescribed as needed at the surgeon's discretion.
Study procedures
After enrolment, we examined all patients to collect baseline data. Study measurements were performed at day 1, weeks 2 and 6, months 3 and 6 and 1 year after surgery. Best-corrected visual acuity was measured with an ETDRS chart. We obtained IOP measurements with a Goldmann applanation tonometer, taking the mean of 3 measurements. Slitlamp and Seidel tests were carried out at every visit; gonioscopy (Volk 4 mirror goniolens) and ophthalmoscopic fundus examinations were executed preoperatively and at 6 months and 1-year follow-up. Visual fields were assessed by a quantitative automated HFA 24-2 (Carl Zeiss Meditec, CA, USA) SITA test. We measured laser flare counts with a Kowa FM-600 (Kowa Company Ltd., Tokyo, Japan). An orthoptist interviewed the patients about the presence of any diplopia and evaluated the motility of the eye(s). All postoperative complications at both scheduled and unscheduled visits were recorded.
Outcome measures
Primary outcome measures were IOP and failure rate at 1 year. We started applying failure criteria from 3 months of follow-up and not earlier, as the BGI will only commence managing the IOP after 4 to 6 weeks. Failure was defined as persistent intraocular hypertension (IOP > 21 mmHg), hypotony (IOP ≤ 5 mmHg), or less than 20% reduction relative to baseline IOP for at least two consecutive examinations. The latter is an important criteria for NTG patients. Reoperation for glaucoma was also defined as a failure. Furthermore, we evaluated failure after narrowing down the acceptable IOP range (from the initial 5-21 to 5-17) and 5-14 mmHg. The ophthalmologist could prescribed patients IOP lowering medication when the IOP was not in the desired IOP range (defined by the ophthalmologist for each individual patient within the acceptable IOP range of 5-21 mmHg). Success was defined as 'qualified' when additional medication was needed and as 'complete' when not. Secondary outcome measures were IOP during all follow-up visits, additional medication to lower IOP, laser flare counts and complications.
Statistical analysis
Sample size was calculated with a standard deviation (SD) of the IOP of 5.5 mmHg (Gedde et al.2007 ) and an equivalence limit of 2.5 mmHg. With a two-sided significance level of a=0.05, a power of 0.80 and adjustment for 15% drop out, a group size of 90 would be sufficient (Abramson 2011) . At an interim evaluation (1-year follow-up; 40 subjects per group), the SD proved to be 4.2. Therefore, an amendment (approved by the ethical committee) of sample size (SD=4.5 mmHg, other parameters unchanged) reduced group size to 60, that is, 120 patients in total. Univariable analysis of possible differences between the two treatments was performed using the two-sided t-test for independent samples (age and IOP) or the Mann-Whitney U-test (flare count). Categorical variables were evaluated with either the chi-square or Fisher's exact test. Kaplan-Meier analysis (log-rank test) was performed to compare failure rates of the two treatment groups. Statistical analyses were performed using SPSS software (version 21; SPSS, Inc., Chicago, Illinois, USA).
Results

Baseline
Between July 2008 and September 2014, we recruited 119 subjects. All 119 patients completed the follow-up with a median value of 13 months; range 11-15 months. The preoperative characteristics are shown in Table 1 . No significant differences were found between groups with respect to age, gender, IOP, visual acuity, visual field loss, laser flare count or glaucoma subtype diagnosis. Figure 1 presents the baseline and follow-up IOPs for both study groups. Both surgical procedures showed a significant reduction in IOP 1 year after surgery compared to preoperative measurements. In the BGI group, IOP decreased from 23 AE 7 mmHg (mean AE SD) at baseline to 14 AE 4 mmHg at 1 year of follow-up (p < 0.001; paired t-test). In the TE group, IOP was reduced from 21 AE 7 mmHg at baseline to 13 AE 4 mmHg at 1 year of follow-up (p < 0.001; paired t-test). When comparing the difference in mean IOP between the two groups at 1 year, no statistical difference was found (0.7 AE 5.8 mmHg; 95% CI: À0.8 to 2.2 mmHg). However, we observed that during earlier postoperative visits (2 weeks, 6 weeks, 3 months and 6 months), IOP was statistically significantly lower in the TE group (p < 0.001; paired t-test). Table 2 shows the use of glaucoma drugs at baseline and follow-up visits. At baseline, no significant difference was noted in the amount of active substances between treatment groups (p = 0.17; Fisher's exact test). At 1-year followup, we observed a significant reduction in the need for pharmacological therapy in both treatment groups. Significantly, more patients in the TE group (85%) than in the BGI group (25%) could maintain a stable IOP without additional pharmacological therapy (p < 0.001; Fisher's exact test).
Intraocular pressure
Pharmacological therapy
Failure
There was no significant difference in failure rate between treatment groups (p = 0.88). One year after surgery, the cumulative probability of failure was 18% in the TE group and 17% in the BGI group as presented in the reversed Kaplan-Meier curve in Fig. 2 . Most failures occurred around 6 months of follow-up. The most common reason for failure was an insufficient reduction of IOP. In the BGI group, 3 patients failed because of an IOP higher than 21 mmHg. In contrast, no TE patient had a persistent intraocular hypertension (IOP>21 mmHg). Only one patient developed persistent hypotony. Resurgery as a result of inadequate IOP control did not occur. In both groups, the main reason of failure was a reduction of less than 20% at two consecutive visits.
When we replace the first criterion, definition of failure (IOP>21 mmHg), by IOP>17 mmHg, failure rate was 22% in the BGI group versus 18% in the TE group. Lowering the upper limit to 14 mmHg, failure rates were 34% and 22%. In both instances, the other criteria were also taken into account, that is hypotony (IOP ≤ 5 mmHg), or less than 20% reduction relative to baseline IOP or resurgery for glaucoma. Irrespective of definition, failure rates did not statistically significantly differ between the two procedures at one year after surgery (p = 0.59 and p = 0.13; log-rank test).
As for success rate (with or without additional medication), no significant difference was present at 1 year postoperatively (p = 0.88; log-rank test). However, complete success (without medication) was significantly higher in the TE group (75% versus 22%).
Visual function
Visual acuity (VA) was in the TE group 0.08 AE 0.23 at baseline and 0.11 AE 0.27 at 1 year after surgery. In the BGI group, VA was 0.06 AE 0.25 at baseline and 0.08 AE 0.25 at 1 year after surgery. Neither visual acuity nor visual field showed significant changes, and no statistically significant differences between groups were observed at any time during follow-up.
Flare count
Preoperative flare value in the two study groups was similar (p = 0.09, MannWhitney test). Flare increased after surgery with both procedures. After 6 or more weeks, flare was significantly higher in the BGI group (p < 0.001) (Fig. 3) . At 1 year, the flare value still did not return to baseline level in the BGI group.
Complications
One year postoperatively, 54 (90%) patients of the TE group were free of complications versus 49 (83%) in the BGI group (Table 3) . Hyphema was mainly observed during the first two weeks after surgery and more frequently in the TE group (17% in BGI group versus 32% in TE group). In the BGI group, two patients experienced a high IOP as a result of a steroid response. One case of hypotony occurred in the TE group resulting in maculopathy. No significant difference was found with respect to other complications (choroidal effusion, cataract formation, peripheral anterior synechiae disorder and shallow anterior chamber), most of which resolved without further intervention. In total, 5 patients required resurgery due to complications; 3 patients in the BGI group and 1 patient in the TE group needed cataract extraction within 1 year after surgery. In the TE group, 1 patient with a conjunctiva tear was rescheduled the day after surgery. Concerning the occurrence of diplopia, a significant difference was found between the two study groups (p < 0.001; chi-square test). At 1 year after BGI placement, 16 patients (28%) reported diplopia. Seven patients had diplopia in any of the gaze directions, 7 patients suffered of intermittent diplopia in primary and/or reading position, and 2 patients experienced continuous diplopia in primary and/or reading position. In the TE group, only 2 patients (3%) reported diplopia. No explantation of the BGI was carried out during the first year, but 2 patients received prism glasses in an attempt to treat the diplopia.
Discussion
With an equivalence limit of 2.5 mmHg, our study demonstrates that at 1 year of follow-up, the final IOP was equivalent for trabeculectomy (13 AE 4 mmHg) and a BGI (14 AE 4 mmHg). Concerning IOP reductions, both surgical procedures obtained similar results; 38% reduction in the TE group and 40% in the BGI group. To achieve the desired level of IOP reduction, however, the BGI group required more supplemental pharmacological therapy. Initially, IOP was observed to diverge during followup but, eventually, converged after 1 year (Fig. 1) . Trabeculectomy (TE) showed immediate IOP control, while the BGI required a temporary reduction of aqueous flow (achieved by applying a soluble suture around the tube). This prevents hypotony until a fibrous encapsulation of the plate develops, during which only a fenestration can lower IOP. After 4 to 6 weeks, the suture dissolves and the aqueous flow towards the BGI commences (and thus the more permanent management of the IOP). Furthermore, similar failure rates for the two groups were observed; 18% for TE and 17% for the BGI (p = 0.88).
In the past, studies with similar design and with identical criteria for outcome measures have compared GDD to TE. For example, a randomized clinical trial with 117 subjects (AVT study) compared the Ahmed glaucoma valve (AGV) to trabeculectomy (Wilson et al. 2003 ). Although The table reports the number of patients using 0, 1, 2, 3, 4 or more types of glaucoma medication in the course of 1-year follow-up by treatment group. All 119 patients completed 1 year of follow-up. * Fisher's exact test.
the glaucoma device differed, the study population was similar to that of the present study and comparable success rates were reported. However, IOP management with the AGV appeared to take more time than for the BGI: at 1 year, IOP was still significantly higher in the AGV group (p = 0.01). Consistent with our findings, the implant group required more additional medication.
In the tube versus trabeculectomy study (TVT study), the long-term follow-up of a BGI and TE was compared (Gedde et al. 2007) . Contrary to the patients in our study, TVT patients had a history of ocular surgery such as cataract surgery, trabeculectomy or both. After 1 year, IOP reduction showed no statistically significant difference between both groups (p = 0.055). As in the AVT study and our study, the use of medication was significantly less after TE (p < 0.001). Remarkably, the BGI group of the TVT study shows a very low failure rate (4%).
A retrospective review of medical records of 125 patients who underwent primary glaucoma surgery (TE or BGI) also reports satisfactory IOP management for both groups (Panarelli et al.2016) . Although, as in the AGV study, IOP control by means of the GDD appeared to take a little longer than after TE: at 1 year, the IOP in the TE group was significantly lower (p = 0.016) but after follow-up of 4 more years, no more significant differences were observed. Again, the medication use was significantly less after TE at 1 year.
Contrary to the TVT study, we found no significant decrease in visual acuity or visual field. A reason for this difference in results could be the severity of glaucoma in the operated eye. Kashiwagi et al. (2016) found that eyes with a worse preoperative visual acuity showed a higher incidence of blindness. The preoperative visual acuity in the TVT study (0.37 AE 0.38 in TE group and 0.42 AE 0.54 in BGI group) was significantly worse than in our study (0.08 AE 0.23 in TE group and 0.06 AE 0.25 in BGI group).
A previous study has shown that photon (or flare) count is linearly related to protein concentration in the eye (Shah et al. 1991) . Aqueous cells and an increased flare value are caused by a breakdown of the blood-aqueous barrier because of infection or inflammation, as a reaction to surgery or a foreign body (Shah et al. 1991) . In our study, two weeks after TE, flare reached a maximum and returned to baseline after 6 weeks. From week 6 until month 12, flare values in the BGI The presented complications are the cumulatively observed events during any follow-up visit within 1 year after surgery. * Number of patients without complications at 1 year after surgery. † In primary and/or reading position.
group were significantly higher than in the TE group, which indicates increased protein contents in the aqueous fluid. The presence of a foreign body, that ise. the silicone tube, causes a prolonged inflammation during the healing response and may result in higher flare values in the anterior chamber than in the TE group. The flare values after cataract surgery, where also a foreign body is inserted, increase directly after surgery and return to baseline level after 3 months (Shah & Spalton 1994) . Studies suggest this postoperative elevation of flare values is related to a fibrotic reaction of the lens capsule fibroses to the implant (Shah & Spalton 1994) , a suggestion we also considered in case of the tube in the anterior chamber. Complication rates at 1 year postoperatively did not significantly differ between the BGI group (17%) and the TE group (10%). After TE, patients were more likely to experience early complications, such as hyphema. This may be due to the peripheral iridectomy that is part of the TE procedure and is known to increase the risk of hyphema (Moura & Sit 2013) . The occurrence of choroidal effusion was comparable in both groups (12%). Similar incidences of early postoperative choroidal effusion have been reported before: 13% for TE versus 14% for the BGI (Gedde et al. 2012 ). All complications mentioned above were self-limiting or manageable. Furthermore, no corneal decompensation or stromal changes have been observed, although literature suggests a significant corneal endothelial cell loss after BGI surgery (Tan et al. 2017) .
Nonetheless, a well-known and serious complication of GDD is diplopia, which interferes with the daily tasks of the patient (Christmann & Wilson 1992) (Rauscher et al. 2008 ) (Chang 2014) . Diplopia occurred more frequently in the BGI group. Only 2 patients in the TE group experienced diplopia. But, both TE patients were biased; 1 patient received a BGI in the fellow eye and 1 had a trauma, which could have influenced the orbital morphology.
The TVT study also mentioned the occurrence of diplopia. But, contrary to our study, they did not differentiate by severity. (Rauscher et al. 2008; Gedde et al. 2012) . We can only compare the incidence of persistent diplopia between the two studies. The incidence of persistent diplopia was slightly higher in the TVT study (5%) than in our study (2%). The lower incidence in our study may be explained by having a younger study group (60.1 AE 7.6 years vs 71.3 AE 9.6 years) and the fact that none of our patients had a history of ocular surgeries, contrary to the patients in the TVT study.
Because of its single-centre and single-surgeon design, the inclusion period for this study was rather long. For the same reason, surgical procedures were fairly uniform. This study may not warrant extrapolation to other patient groups (e.g. non-Caucasians or patients with ocular history) or other glaucoma devices. A 1 year of followup is a relatively short follow-up time. Because life-time expectancy for Europeans and North Americans is approximately 80 years (WHO, 2016) and GDD may be implanted well in advance of reaching such an age (approximately 60 years old in this study), it is important to investigate their longterm efficacy. Therefore, data collection for our study will continue until 5 years of follow-up.
The TVT study published their 5 years of follow-up (Gedde et al. 2012) . The failure rate of the TE was significantly higher than in the BGI group (50% versus 33%). The TE group had a progressive increase in the use of additional IOP lowering medication during the 5 years of follow-up, resulting in a similar rate of complete success as in the BGI group (29% versus 25%). Also, the rate of resurgery was higher in the TE group than in the BGI group. These findings suggest that the BGI performs better in the long run, while the TE has better short-term results.
Overall, we conclude that, after 1 year, TE shows better results than the BGI. The IOP reduction and failure rate are similar, but the need for additional IOP lowering medication in the BGI group is higher as well as the overall complication rate, particularly the occurrence of diplopia. Further follow-up is required to study whether these differences persist.
From the point of view of clinical relevance, we should discuss whether TE or a GDD is preferred when surgical IOP reduction is required. If immediate reduction of IOP is desired, a TE could be the better option than a Baerveldt placement because the pressure control in the first year is better in the TE group (Fig. 1) . As the BGI needs more supplemental medication to lower IOP, a patient with an intolerance or poor compliance can also be scheduled for a TE. On the other hand, a TE requires more follow-up after surgery. Based on the IOP development during the first year (Fig. 1) , it might be worthwhile to wait minimally 1 year after placement of a BGI before interfering and considering a second pressure lowering IOP surgery. The long-term (5 years) followup results of the TVT study confirm that the IOP in the BGI group reduces and stays stable after year one, while in the TE group, the IOP rises year after year. The 5 years of follow-up results of our study will, in due course, reveal whether this also applies for a study population without previous ocular surgery.
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